Global Barth Syndrome Treatment Market, By Application (Dilated Cardiomyopathy, Skeletal Myopathy, Neutropenia, Others), Treatment (Antibiotics, Granulocyte Colony Stimulating Factor (GCSF)) – Industry Trends and Forecast to 2030.
Barth Syndrome Treatment Market Analysis and Size
Most males suffering from barth syndrome have neutropenia. Males with Barth syndrome have augmented levels of a substance named as 3-methylglutaconic acid in their blood and urine. Barth syndrome is projected to affect around 1 in 300,000 to 400,000 individuals globally. More than 150 cases have been described till date.
Data Bridge Market Research analyses a growth rate in the barth syndrome treatment market in the forecast period 2023-2030. The expected CAGR of barth syndrome treatment market is tend to be around 13% in the mentioned forecast period. The market was valued at USD 126.01 billion in 2022, and it would grow up to USD 335 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Barth Syndrome Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Application (Dilated Cardiomyopathy, Skeletal Myopathy, Neutropenia, Others), Treatment (Antibiotics, Granulocyte Colony Stimulating Factor (GCSF)), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Amneal Pharmaceuticals LLC. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Abbott (U.S.) B Braun SE (Germany), Integra LifeSciences (U.S.), Johnson & Johnson Services, Inc. (India), Medtronic (Ireland), MicroPort Scientific Corporation (China), NuVasive, Inc (U.S.), Orthofix US LLC (U.S.), Perrigo Company plc. (Ireland), Stryker (U.S.), Zimmer Biomet (U.S.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Barth syndrome is a rare type of genetic lipid metabolism disorder that primarily affects the males. It happens because of mutation in a TAZ gene that declines the enzyme production of cardiolipin. Symptoms include weakness, less mobility of muscles and others. In males suffering from Barth syndrome, dilated cardiomyopathy often exist at birth or develops within the first months of life
Barth Syndrome Treatment Market Dynamics
Drivers
- Growing Prevalence Of Barth Syndrome
Barth syndrome affects almost all ethnic groups. The prevalence of barth syndrome is projected to be around 1 in 300,000 to 1 in 400,00 in U.S. As of 2013, there have been around 151 patients reported. Thus, this increasing prevalence boosts the market growth.
- Increased Diagnosis of Barth Syndrome
Barth syndrome is generally diagnosed during infancy or early childhood, but has been diagnosed later in many patients. Multiple pregnancy losses which involves a male fetus have been witnessed in some families with barth syndrome. Molecular genetic testing for mutations in the TAZ gene checks the diagnosis of barth syndrome. The TAZ gene testing can be done either individually or as a part of a multigene panel. Thus, these varied diagnostic methods are boosting the faster treatment processes.
Opportunities
- Growing Treatment Methods
Many standard heart failure medications have been used, such as beta blockers, ACE inhibitors and digoxin. This helps in improving the heart function and decreases symptoms of heart failure. Furthermore, aspirin is used for decreasing clot formation. Heart transplant is also considered when there is extreme heart failure. The heart functioning tends to improve post infancy, so heart transplant should be carefully considered. Genetic counseling is also recommended for affected individuals and their families. Other treatment for this disorder is symptomatic and much supportive. Thus, all these treatment methods are boosting the growth of the market.
Restraints/Challenges
- High Cost of Treatment
The huge expenditure required for the surgeries and treatment processes impedes market growth. Several market players make several huge investments in manufacturing new and advanced treatment procedures to fasten the recovery process, and in return, the cost is increased.
This barth syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the barth syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Barth Syndrome Treatment Market Scope
The barth syndrome treatment market is segmented on the basis of application, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Dilated Cardiomyopathy
- Skeletal Myopathy
- Neutropenia
- Others
Treatment
- Antibiotics
- Granulocyte Colony Stimulating Factor (GCSF)
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Barth Syndrome Treatment Regional Analysis/Insights
The barth syndrome treatment market is analyzed and market size insights and trends are provided by application, treatment, distribution channel and end-user as referenced above.
The major countries covered in the barth syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period due to the increasing prevalence of neurological disorders and mounting technological advancements.
Asia-Pacific is considered to grow over the coming years because of the increasing public awareness and increasing healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Barth Syndrome Treatment Share Analysis
The barth syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to barth syndrome treatment market
Key players operating in the barth syndrome treatment market include:
- Amneal Pharmaceuticals LLC. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Abbott (U.S.)
- B Braun SE (Germany)
- Integra LifeSciences (U.S.)
- Johnson & Johnson Services, Inc. (India)
- Medtronic (Ireland)
- MicroPort Scientific Corporation (China)
- NuVasive, Inc(U.S.)
- Orthofix US LLC (U.S.)
- Perrigo Company plc. (Ireland)
- Stryker Corporation (U.S.)
- Zimmer Biomet (U.S.)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
SKU-